JP2019507791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507791A5 JP2019507791A5 JP2018547929A JP2018547929A JP2019507791A5 JP 2019507791 A5 JP2019507791 A5 JP 2019507791A5 JP 2018547929 A JP2018547929 A JP 2018547929A JP 2018547929 A JP2018547929 A JP 2018547929A JP 2019507791 A5 JP2019507791 A5 JP 2019507791A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- dihydroxybutan
- sulfonamide
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078242A JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307348P | 2016-03-11 | 2016-03-11 | |
| US62/307,348 | 2016-03-11 | ||
| PCT/US2017/021570 WO2017156270A1 (en) | 2016-03-11 | 2017-03-09 | Cxcr-2 inhibitors for treating crystal arthropathy disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078242A Division JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507791A JP2019507791A (ja) | 2019-03-22 |
| JP2019507791A5 true JP2019507791A5 (ja�@�@) | 2020-04-30 |
| JP6883917B2 JP6883917B2 (ja) | 2021-06-09 |
Family
ID=59789863
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547929A Expired - Fee Related JP6883917B2 (ja) | 2016-03-11 | 2017-03-09 | 結晶性関節障害を処置するためのｃｘｃｒ−２阻害剤 |
| JP2021078242A Active JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078242A Active JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10772886B2 (ja�@�@) |
| EP (1) | EP3426253A4 (ja�@�@) |
| JP (2) | JP6883917B2 (ja�@�@) |
| CN (2) | CN113893252A (ja�@�@) |
| AU (1) | AU2017231832B2 (ja�@�@) |
| BR (1) | BR112018068393A2 (ja�@�@) |
| CA (1) | CA3017345A1 (ja�@�@) |
| CO (1) | CO2018010880A2 (ja�@�@) |
| MX (1) | MX386771B (ja�@�@) |
| WO (1) | WO2017156270A1 (ja�@�@) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113893252A (zh) | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| JP2020533332A (ja) * | 2017-09-12 | 2020-11-19 | アルデア バイオサイエンシーズ インク． | 障害を処置するためのｃｘｃｒ−２阻害剤 |
| CN111727184B (zh) * | 2018-01-11 | 2022-06-28 | 深圳嘉科生物科技有限公司 | Cxcr2拮抗剂 |
| US12577235B2 (en) | 2019-07-11 | 2026-03-17 | Shenzhen Optimum Biological Technology Co., Ltd | Crystalline form of CXCR2 antagonist and application thereof |
| KR102260478B1 (ko) * | 2019-08-19 | 2021-06-02 | 연세대학교 산학협력단 | 일나트륨 요소화물 결정 용해용 조성물 |
| TW202210068A (zh) * | 2020-06-05 | 2022-03-16 | 美商雅力思提雅治療公司 | 用於治療家族性地中海型發熱病的cxcr-2抑制劑 |
| WO2022162021A1 (en) * | 2021-01-27 | 2022-08-04 | Astrazeneca Ab | Verinurad compositions and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| RU2388756C2 (ru) | 2004-01-30 | 2010-05-10 | Шеринг Корпорейшн | Кристаллические полиморфные формы лиганда схс-хемокинового рецептора |
| EP2311827A1 (en) * | 2004-08-28 | 2011-04-20 | AstraZeneca AB | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators. |
| CN101646440A (zh) | 2007-01-19 | 2010-02-10 | 武田制药北美公司 | 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法 |
| EP2203432A4 (en) | 2007-09-21 | 2011-04-27 | Glaxosmithkline Llc | PROCESSING METHOD |
| US20090093548A1 (en) | 2007-10-05 | 2009-04-09 | Mutual Pharmaceutical Company, Inc | Colchine compositions and methods |
| EP2252327A2 (en) | 2007-12-04 | 2010-11-24 | Schering Corporation | Methods of treating copd |
| NZ588033A (en) | 2008-03-20 | 2012-11-30 | Carolus Therapeutics Inc | Methods of treating a mif-mediated disorder |
| KR20110031462A (ko) | 2008-07-16 | 2011-03-28 | 아스트라제네카 아베 | 피리미딜 술폰아미드 유도체 및 케모카인 매개 질환의 치료를 위한 그의 용도 |
| CA2737924A1 (en) | 2008-10-06 | 2010-04-15 | Joshua Robert Schultz | Methods of treating inflammation |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| WO2010056399A1 (en) | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| WO2010065491A2 (en) | 2008-12-01 | 2010-06-10 | Carolus Therapeutics, Inc. | Methods of treating inflammatory disorders |
| WO2010071865A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| WO2010124296A2 (en) | 2009-04-24 | 2010-10-28 | Tissuetech, Inc. | Compositions containing hc•ha complex and methods of use thereof |
| CN102725311A (zh) | 2009-09-23 | 2012-10-10 | 卡罗勒斯治疗公司 | 治疗发炎的方法 |
| WO2011116245A2 (en) | 2010-03-19 | 2011-09-22 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
| CA2804162A1 (en) | 2010-07-13 | 2012-01-19 | Astrazeneca Ab | New crystalline forms of n-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1r,2s)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl}-1-azetidinesulfonamide |
| EP2608672B1 (en) * | 2010-08-23 | 2020-12-16 | Syntrix Biosystems, Inc. | Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
| SI3255043T1 (sl) * | 2011-07-12 | 2021-04-30 | Astrazeneca Ab | N-(6-((2R,3S)-3,4-dihidroksibutan-2-iloksi)-2-(4-fluorobenziltio) pirimidin-4-il)-3-metilazetidin-1-sulfonamid, kot modulator kemokinskega receptorja |
| EP3838293A1 (en) | 2012-07-11 | 2021-06-23 | Tissuetech, Inc. | Compositions containing hc-ha/ptx3 complexes and methods of use thereof |
| EP3220951A1 (en) | 2014-11-17 | 2017-09-27 | MedImmune Limited | Therapeutic combinations and methods for treating neoplasia |
| US20180221312A1 (en) | 2016-03-11 | 2018-08-09 | Ardea Biosciences, Inc. | Cxcr-2 inhibitors for treating disorders |
| CN113893252A (zh) | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| JP2020533332A (ja) | 2017-09-12 | 2020-11-19 | アルデア バイオサイエンシーズ インク． | 障害を処置するためのｃｘｃｒ−２阻害剤 |
-
2017
- 2017-03-09 CN CN202111152242.9A patent/CN113893252A/zh active Pending
- 2017-03-09 EP EP17764095.0A patent/EP3426253A4/en not_active Withdrawn
- 2017-03-09 CN CN201780029205.4A patent/CN109152780B/zh active Active
- 2017-03-09 JP JP2018547929A patent/JP6883917B2/ja not_active Expired - Fee Related
- 2017-03-09 MX MX2018010946A patent/MX386771B/es unknown
- 2017-03-09 CA CA3017345A patent/CA3017345A1/en active Pending
- 2017-03-09 BR BR112018068393A patent/BR112018068393A2/pt not_active Application Discontinuation
- 2017-03-09 AU AU2017231832A patent/AU2017231832B2/en not_active Ceased
- 2017-03-09 WO PCT/US2017/021570 patent/WO2017156270A1/en not_active Ceased
- 2017-03-09 US US15/516,465 patent/US10772886B2/en not_active Expired - Fee Related
-
2018
- 2018-10-10 CO CONC2018/0010880A patent/CO2018010880A2/es unknown
-
2021
- 2021-05-05 JP JP2021078242A patent/JP7126014B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507791A5 (ja�@�@) | ||
| JP6434416B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| BR0309670A (pt) | Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo | |
| US20110046119A1 (en) | Therapeutic treatment | |
| JP2005502643A (ja) | 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用 | |
| JP2015535247A5 (ja�@�@) | ||
| JP7460772B2 (ja) | コロナウイルス感染症の治療方法 | |
| JP2012184234A5 (ja�@�@) | ||
| KR20150046039A (ko) | 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제 | |
| JP2013528655A5 (ja�@�@) | ||
| BR112015010063A2 (pt) | método para o tratamento ou prevenção de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, utilização de um composto de fórmula (i), um derivado da colquicina conhecido e/ou um sal do mesmo, composição para a prevenção ou tratamento de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, método e regime para reduzir ou prevenir a inflamação induzida por cristal de colesterol no interior das placas ateroscleróticas em um sujeito, regime para o tratamento ou prevenção de um acidente cardiovascular em um indivíduo | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| RU2013145498A (ru) | Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией | |
| JP2014532726A5 (ja�@�@) | ||
| JP2013500977A5 (ja�@�@) | ||
| MA46268A (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| RU2009111378A (ru) | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5 | |
| TW201912153A (zh) | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 | |
| BR112020018601A2 (pt) | Regime de dosagem de modulador de montagem de capsídeo | |
| RU2014115733A (ru) | Новая соль и медицинское применение | |
| JP2013087119A5 (ja�@�@) | ||
| KR20230048517A (ko) | 베타 코로나바이러스 감염과 연관된 질환을 치료 또는 예방하기 위한 조성물 및 방법 | |
| JP2020536890A (ja) | 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ | |
| JP2015526504A5 (ja�@�@) | ||
| CN1681533A (zh) | 用于治疗动脉硬化的药用组合物 |